Advances in the allogeneic transplantation for thalassemia.

Advances in the allogeneic transplantation for thalassemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Advances in the allogeneic transplantation for thalassemia. Abstract Text:

Hematopoietic stem cell transplantation (HSCT) remains the only curative option for patients with thalassemia. Current results of transplantation in patients aged less than 17 years from matched related donors offer 80% to 87% probability of cure according to risk classes. Adult thalassemics treated with myeloablative conditioning continue to have inferior results because of their advanced stage of disease. With the introduction of high-resolution tissue typing techniques transplant centres worldwide are able to offer allogeneic HSCT to a much larger cohort of patients who could not benefit from transplantation because of lack of matched family donor. Although limited number of patients treated, results of transplant from unrelated matched donors are comparable to those obtained using sibling donors. Graft failure or rejection remains a significant cause of transplant failure in patients with thalassemia making difficult to perform reduced intensity conditioning regimens. Mixed chimerism is a common phenomenon after transplantation and is a risk factor for rejection. Ex-thalassemics still carry the clinical complications acquired during years of transfusion and chelation therapy. Longer follow-up and management of these complications in ex-thalassemics are essential.

Advances in the allogeneic transplantation for thalassemia. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Advances in the allogeneic transplantation for thalassemia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Blood reviews

VOLUME: 22

Page Numbers: 53-63

Journal Abbreviation: Blood Rev.

ISSN: 0268-960X

DAY: 26

MONTH: 11

YEAR: 2007

Advances in the allogeneic transplantation for thalassemia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8708558

Advances in the allogeneic transplantation for thalassemia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Advances in the allogeneic transplantation for thalassemia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Advances in the allogeneic transplantation for thalassemia.

AFFILIATION: Director, International Centre for Transplantation in Thalassemia and Sickle Cell Anemia, Mediterranean Institute of Hematology, Rome 00133, Italy.

Country: Scotland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Advances in the allogeneic transplantation for thalassemia Related Publications

• Advances in the allogeneic transplantation for thalassemia.
• [Changes in the composition of the nuclear matrix proteins of Zajdela hepatoma cells with novobiocin inhibition of DNA replication]
• [Damage and recovery of the DNA-membrane complex of Bacillus subtilis following exposure to gamma-radiation]
• [Morphology of the pancreas during intra-aortal administration of 5-fluorouracil]
• [Sharp changes in the copy number of mtDNA and its transcription in the blood cells of X-ray irradiated mice are observed, and mtDNA fragments appear in the blood serum]
• [The genotoxic effects of cadmium studied in vivo]
• [The nature of gamma-induced double-stranded DNA breaks in E. coli cells]